SINGAPORE, Sept 24 (Reuters) - Pfizer Inc (PFE.N) is in discussions with Singapore's Health Sciences Authority regarding obtaining a full license application for its COVID-19 vaccine, the company said in response to a query from Reuters.
Pfizer-BioNTech's (22UAy.DE) COVID-19 vaccine has interim authorisation under the pandemic special access route in Singapore. The U.S. Food and Drug Administration granted full approval to the vaccine last month. read more
Kenneth Mak, Singapore's director of medical services, said in a briefing on Friday Pfizer and Moderna (MRNA.O) had not submitted applications for full registration to authorities.
Singapore has not made COVID-19 vaccination compulsory, saying the Pfizer and Moderna shots only have emergency approval, although it has limited activities such as eating out for the unvaccinated.
Our Standards: The Thomson Reuters Trust Principles.